TFFP - TFF Pharma announces 'positive' results for its drug delivery platform
TFF Pharmaceuticals (TFFP) announces that the company obtained positive preclinical in vitro efficacy data regarding the thin film freezing ("TFF") formulated biodefense countermeasures.The studies were conducted in collaboration with the United States Army Medical Research Institute of Infectious Diseases.TFFD formulations of the first two countermeasures, a monoclonal antibody (mAbs) against Ebolavirus Zaire and a recombinant vesicular stomatitis virus (“rVSV”) vaccine candidate against Venezuelan equine encephalitis virus were subject to an in vitro neutralization assay to test efficacy.The data has indicated that the activity of the mAbs and rVSV vaccines were preserved after TFFD. The tests are underway for formulation optimization and long-term stability testing with in vivo testing planned in appropriate animal models.The TFF platform is designed to improve the solubility and absorption of poorly water-soluble drugs and it can be used to generate dry powder particles targeting the inhalation delivery, especially to the deep lung, the company said in a statement.Last
For further details see:
TFF Pharma announces ‘positive’ results for its drug delivery platform